Caris Life Sciences, an Irving-based next-generation AI TechBio company and precision medicine pioneer, announced that the U.S. Food and Drug Administration has approved MI Cancer Seek for use as a companion diagnostic to identify cancer patients who may benefit from treatment with targeted therapies.
“FDA approval of MI Cancer Seek — the first of its kind — further demonstrates Caris’ continued leadership in molecular science and our extreme focus on quality,” Caris Founder, Chairman, and CEO David Dean Halbert said in a statement. “We’re thrilled to bring MI Cancer Seek to market to ensure patients have access to critical precision medicine tools.”
Caris said the assay includes one pan-cancer and five tumor-specific indications for numerous FDA-approved therapies.
The company said that MI Cancer Seek is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors.
MI Cancer Seek is available for adults and pediatric patients, ages 1-22, Caris said.
How it works and what it does
The company said that MI Cancer Seek is a next-generation sequencing (NGS) based in vitro diagnostic (IVD) device using total nucleic acid isolated from formalin-fixed paraffin-embedded tumor tissue specimens for the detection of single nucleotide variants (SNVs) and insertions and deletions in 228 genes, microsatellite instability, and tumor mutational burden in patients with previously diagnosed solid tumors, and copy number amplification in one gene in patients with breast cancer.
MI Cancer Seek is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table, in accordance with the approved therapeutic product labeling, Caris said. Also, MI Cancer Seek is intended to provide tumor mutational profiling to be used by qualified healthcare professionals in accordance with professional oncology guidelines for cancer patients with previously diagnosed solid malignant neoplasms.
“We’re very excited to receive FDA approval for our MI Cancer Seek test. The extensive rigor with which the FDA evaluates new technology ensures patients have access to safe and effective tests,” Caris President David Spetzler said in a statement. “The process of working with the FDA was both collaborative and insightful, and we applaud their expertise in the evaluation of novel technologies.”
Typically, DNA and RNA analysis by NGS requires two separate testing processes that may require more tissue and time.
By combining WES and WTS into one workflow, MI Cancer Seek provides a comprehensive molecular blueprint that saves tissue without compromising results.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
“The approval of ZUNVEYL is a pivotal moment in the fight against Alzheimer's disease as it's only the second oral AD treatment to be approved in more than a decade," said CEO Michael McFadden of Alpha Cognition. Based in Vancouver with an office in Frisco, the company was honored at the 2023 BioNTX iC3 Summit as one of eight "Rising Stars."
-
The UT Southwestern researchers' noninvasive model uses a standard MRI, paired with machine learning AI, to detect the presence of cancer cells in the lymph nodes under the arms.
-
Included in the 12 Dallas-area funding awards is a $4 million Rising Star grant to bring Stefan Gloeggler, Ph.D., to UT Southwestern Medical Center from the Max Planck Institute of Multidisciplinary Sciences in Göttingen, Germany.
-
Researchers at Children's Hospital of Philadelphia and UT Southwestern analyzed T-cell receptors in nearly 500 blood samples from pre-diagnostic patients with ovarian cancer. The results point to the potential of testing for biomarkers 2 to 4 years before most cases of HGOC are currently diagnosed.
-
Premature babies diagnosed with bronchopulmonary dysplasia (BPD) face the risk of rehospitalization, delayed brain development, and respiratory problems throughout childhood. No FDA-approved therapies are available for BPD—which is why the new FDA designation for AyuVis's drug candidate, AVR-48, could lead to game-changing impact.
